A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

December 5, 2022 · Fortune

Florian Brand knows that there aren’t many people with his profile in biopharma. “You would probably consider me an outlier,” says the 36-year-old chief executive of Germany’s up-and-coming Atai Life Sciences. He doesn’t have a Ph.D. or any scientific background. His previous gig was running an online cookware retailer. But he does possess a history of profound experiences with mental health—experiences that left such an impression that four years ago he dropped everything to cofound Atai, a biopharmaceutical company now backed by investors including Peter Thiel and Cathie Wood. 

Berlin-based Atai is at the forefront of a broadening push to tackle mental health disorders with substances like psilocybin (“magic mushrooms”) and ketamine that have been illegal in many countries for decades. Atai employs an unusual “hub-and-spoke” model, acting as an umbrella for a collection of companies—that Atai either founded or bought a large stake in—each conducting trials on individual substances. Brand’s leadership of this unusual company has landed him on the latest Fortune 40 Under 40 list(Full Story)

In categories:Psychedelics Research
Next Post

Numinus In Strong Position To Capture US$2.5 Billion Psychedelic-Assisted Therapy Market

As the COVID pandemic broke open quite clearly, never has there been a greater need for innovation to treat psychological disorders. With the World Health Organization (WHO) declaring mental health disorders as the leading cause of disability worldwide – nearly a billion…
Read
Previous Post

How Psychedelics Can Transform End-of-Life Care

Welcome to State of Mind, a new section from Slate and Arizona State University dedicated to exploring mental health. Follow us on Twitter. If you’re on TikTok or Instagram, you may have encountered one of nurse Julie McFadden’s viral videos about all…
Read
Random Post

Texas House Committee Considers Raising THC Limits for Medical Cannabis Products

The Texas House Public Health Committee on Monday heard hearings on a bill that would expand the state’s medical cannabis program, FOX 44 reports. The measure would allow access to products with THC levels as high as 5%. Under current law, patients can only access…
Read
Random Post

FDA Says CBD Still Can't Be Dietary Supplement

The agency called on Congress to develop a better regulatory framework for CBD The U.S. Food and Drug Administration this week announced that it would deny a trio of petitions that requested authorization for cannabidiol (CBD) to be used as a…
Read
Random Post

New Yorkers Vent Frustrations over Adult-Use Cannabis Program

From sparse enforcement to lack of transparency, program participants are frustrated. The New York adult-use cannabis program has been fraught with challenges, and many stakeholders are willing to express their frustrations. But a conference hosted in Albany, New York, by…
Read
Random Post

A Seat on the Titanic? - California Cannabis Sales Dropped in 2022 for the First Time Ever Since Legalization

California, an industry bellwether for the marijuana industry, is seeing signs of contraction For the first time since the state's adult-use market opened five years ago, annual sales for marijuana in California fell in 2022. While Colorado and Oregon dispensaries are now…
Read